tiprankstipranks
Sichuan Kelun-Biotech Gains Approval for SKB571 Trials
Company Announcements

Sichuan Kelun-Biotech Gains Approval for SKB571 Trials

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.

Don't Miss Our Christmas Offers:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval for clinical trials of their novel drug SKB571, targeting solid tumors like lung and gastrointestinal cancers. The company has also secured a $37.5 million payment from Merck & Co., with potential for additional milestone payments and royalties, while retaining commercialization rights in China, Hong Kong, and Macau. Investors are advised to exercise caution as the drug may not ultimately succeed in development and commercialization.

For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App